Background Heart failure and left ventricular systolic dysfunction (LVSD) are increasingly common disorders, with outcomes worse than many cancers. Evidence-based therapies, such as ACE inhibitors and beta-blockers, improve prognosis and symptoms, and reduce healthcare expenditure. However, despite the high prevalence and malignant prognosis, few studies have reported the impact of heart failure and LVSD on overall quality of life and, more crucially, have not researched the elderly or those in the community.
Introduction
Heart failure and left ventricular systolic dysfunction (LVSD) are common conditions, with prevalence in the general population over the age of 45 of at least 2·3% and 1·8% respectively [1] . The incidence of both conditions is rising [2] , and they are especially common in the elderly (15% of people over 85 suffer heart failure) [1] and in at-risk groups [3] . The prognosis of patients with heart failure and LVSD is very poor, effectively malignant, with a median survival of only 1·7 years in men and 3·2 years in women [4] . Physicians may also significantly underestimate the scale of patient reported symptoms of physical ill health [5] . ACE inhibitors [6] and beta-blockers [7] have been shown to improve exercise tolerance and symptoms (usually assessed by the New York Heart Association (NYHA) functional class) in patients with heart failure due to left ventricular systolic dysfunction, as well as to significantly prolong survival and reduce hospitalisation rates. There have been conflicting results as to whether these drugs improve quality of life. The Studies of Left Ventricular Dysfunction (SOLVD) investigators examined quality of life, assessed by their own questionnaire [8] , in the placebo and treatment arms of both their heart failure prevention and treatment studies [9, 10] , and found a limited effect of enalapril on quality of life in the treatment study. This could have been due to such questionnaires not being sensitive to a change in status. Jenkinson et al. [11] studied SF36 results before and 4 weeks after initiation of ACE inhibitor therapy in 61 elderly patients (mean age 81 years) diagnosed as having congestive cardiac failure, and found little difference. However, the patients did not receive echocardiography and NYHA class was not reported. It is probable that some of their cases did not have impaired LVSD [12] , that co-morbidities may have influenced patients' overall quality of life, and that improvements may have occurred over a longer treatment period. Other studies report that ACE inhibitors and beta-blockers improve global quality of life in sufferers [9, 10] , as have other interventions producing symptom gains, such as exercise training [13] and intensive nurse-led outreach programmes [14] . Quality of life in heart failure is probably much more important for patients than is generally supposed [15, 16] . Indeed, 49% of patients, in one qualitative study, were prepared to select therapy that improved quality of life even if the treatment shortened life [17] . However, most published data on quality of life, usually assessed using the Minnesota Living with Heart Failure questionnaire, have been in selected, hospitalbased patients participating in trials. It is not known how representative they are of patients in the community. Furthermore, such research has focused on changes in patients' quality of life following treatment, rather than attempted to estimate the global impact of the disease compared to the population of non-sufferers. Studies have also tended to focus only on physical aspects of quality of life in the large therapeutic studies [18] . The few studies with comparative normative data suggest that heart failure worsens quality of life more than other chronic diseases [19] , and that women may suffer worse impairment [20] . However, these data are limited because heart failure diagnosis in the studies was not determined on the basis of objective tests. Other studies have shown heart failure is associated with depressive illness [21] , and further that this is then linked to a worse heart failure prognosis [22] . It is not known whether patients with asymptomatic LVSD, or patients with causes of heart failure other than LVSD have impaired quality of life.
This paper compares the self-assessed quality of life of patients suffering from definite heart failure and LVSD on objective criteria, with quality of life in those with other cardiac conditions and those with other chronic illnesses, in comparison with non-sufferers from the same randomly selected general population sample. Furthermore, the study explores the association of New York Heart Association (NYHA) functional class with overall quality of life in those with confirmed heart failure.
Methods
This was a prospective substudy of the Echocardiographic Heart of England Screening (ECHOES) study, which was designed to estimate the community prevalence of left ventricular systolic dysfunction (LVSD) and heart failure [1] . The main study was carried out in 16 general practices, selected after stratification for the socioeconomic and geographic diversity of the West Midlands region of England between 1995 and 1999. Patients were randomly sampled from the general population and from patients labelled in 3 diagnostic categories on practice registers. Overall, this comprised a random sample of 3960 patients aged 45 years and older; plus a random sample of 782 with a pre-existing diagnostic label of heart failure, 928 prescribed diuretic medication, and 1062 in groups considered at high risk of heart failure (those with a history of previous myocardial infarction, angina, hypertension or diabetes). Patients in more than one diagnostic group (such as on diuretics and with a history of hypertension) could be included in more than one category, but only if chosen at random from lists of all those in that category, hence a total of 6162 patients were screened.
Patients were invited to attend for screening by letter, with one reminder sent to those who did not respond. All assessments took place in a single visit to the patient's own general practice, where a cardiologist collected the clinical history, including questioning about dyspnoea and classification of New York Heart Association (NYHA) dyspnoea score. Patients were examined and a 12-lead ECG recorded. Echocardiography with Doppler studies was conducted using a Hewlett-Packard Sonos 1500 machine, reported by one of two cardiologists, with validation of a proportion of assessments by a third blinded cardiologist. Patients were diagnosed to have heart failure according to European Society of Cardiology guidelines [23] , which require there to be both symptoms suggestive of heart failure (NYHA class II or worse) and objective evidence of cardiac dysfunction.
All patients participating in the study self-completed the Short Form 36 (SF36) health status questionnaire [24] during the screening visit. In cases where patients are unable to do this unaided, e.g. due to poor sight, assistance was given either by their relatives or a member of the research staff. The SF36 is a shortened version of 149 health status questions, developed from the Rand Corporation's health insurance experiment in the United States of America; minor modifications have been made for the UK standard version. The questionnaire is a generic (i.e. not disease-specific) instrument, validated in the comparison of overall quality of life between patients with different conditions and those with no known disease [25] . The questionnaire assesses eight areas of physical and mental health: physical functioning (PF) (ten items); social functioning (SF) (two items); role limitations due to physical problems (RP) (four items); role limitations due to emotional problems (RM) (three items); mental health (MH) (five items); energy and vitality (E) (four items); pain (P) (two items); and general perception of health (HP) (five items). The 36th item, comparing present health with health 1 year earlier, is not included in these eight variables and is not reported here. The questionnaires were completed by patients prior to any clinical examination.
Analysis
Scores for the eight dimensions were coded, summed and transformed onto a scale from 0 (worst possible health) to 100 (best possible health) using the method described in the user manual [26] . To establish internal reliability Cronbach's alpha statistic was calculated for each dimension [26] . The data are summarised using absolute scores and z-scores for each SF36 dimension for groups of patients with heart failure, related cardiac conditions and selected chronic illnesses. Since quality of life scores vary by age, sex and socioeconomic group [27] , the absolute scores were adjusted for age, sex and social class using multiple regression analysis. Individual regression equations were constructed for each SF36 dimension and diagnostic group. Adjusted means were obtained by applying the mean age, sex and social class of the general population to these regression models. Finally, z-scores were calculated by subtracting the adjusted mean scores of the general population sample from the adjusted mean scores of the disease group and dividing this difference by the adjusted standard deviations of the general population. Missing values were dealt with, according to standard protocol, by imputing the mean responding value for missing values assuming that at least half the population had responded to that SF36 dimension or omission where under half the population responded (Tables 1 and 2 report denominators for each  dimension) .
Z-scores are in units of standard deviation and represent a typical individual's variation from the general population, after adjusting for age, sex and social class. This method of analysis allows presentation of the differences in health profiles [28, 29] . Figures 1 to 6 show the z-scores, with each of the eight measured areas of physical and mental health expressed on the x-axis and magnitude of effect (z-score) on the y-axis.
Data were analysed using SAS statistical software [30] . The West Midlands Multi-centre Research Ethics Committee and Local Research Ethics Committees in the practice districts approved the study. All patients gave written informed consent.
Results
During the study a total of 6162 patients were screened from the general population, clinical heart failure, diuretic and high-risk populations. Six thousand and ninety-one (99%) of the sample completed some sections of the SF36 questionnaire, with 5961 (97%) completing in full or enough to be analysed. Cronbach's ranged from 0·80 to 0·94, suggesting good reliability for all eight dimensions. The SF36 health status scores of patients with verified cardiac and other medical conditions are compared with scores of 3850 (97%) from the total randomly selected population sample of 3960 patients, aged 45 and older.
From all the groups screened, 449 patients were diagnosed to have definite heart failure: 144 due to LVSD alone, 133 due to atrial fibrillation, 61 due to valve disease, and 111 cases with combinations of all three causes. Two hundred and eighty-one were in NYHA class II (short of breath during moderate exertion); 94 were in NYHA class III (short of breath on mild exertion such as washing and dressing); and 74 were in NYHA class IV (symptoms of dyspnoea at rest). In addition, 109 patients were found to have significantly impaired LV systolic function (ejection fraction less than 40%) but with no symptoms of dyspnoea during normal activity (i.e. were in NYHA Class I). Sixty-three (58%) of these patients were taking medication (25 on diuretics, eight on ACE inhibitors and 30 on both).
Three hundred and sixty-six patients out of the 3960 chosen at random from the population aged 45 and older gave a history of arthritis, 85 one of depression, and 121 one of chronic bronchitis or emphysema. Five hundred and seventy five were prospectively chosen with a diagnosis of angina from their GP records, or were in the random population sample and gave a history of angina. Similarly, 431 patients had prior myocardial infarction and 1293 hypertension.
The minimum number of patients who responded within each category and absolute scores for all eight dimensions of the SF36 questionnaire are given in Table 1 LVSD=Left ventricular systolic dysfunction. Table 1 . The adjusted mean scores for all eight dimensions of the SF36, for each of the diagnostic groups after accounting for age, sex and social class are found in Table 2 . Figure 1 shows the z-scores of the patients found to be in heart failure with 95% confidence intervals. Patients in heart failure have statistically significant impairment of all the measured areas of health, not merely physical General population  3850  75·7  76·2  81·0  85·2  76·0  63·5  75·6  70·1  Diagnosed heart failure  426  46·9  41·9  64·2  64·9  69·6  42·6  66·9  48·8  Angina  553  61·0  54·9  70·5  75·4  70·9  51·5  62·5  56·4  History of MI  412  63·7  58·3  72·0  77·9  72·9  55·0  68·1  60·3  High blood pressure  1246  72·1  72·3  78·6  83·5  74·0  60·6  74·0  65·1  Arthritis  350  59·3  56·7  76·3  78·2  75·7  57·4  53·2  61·2  Chronic bronchitis  115  57·7  54·0  61·5  70·5  67·0  49·4  69·0  48·3  Depression  80  69·4  61·0  41·7  62·2  50·6  45·7  65·5  57·8  ALVD --=general population; =95% confidence interval; =diagnosed heart failure. NB for all figures: Scores more extreme than 0·8 are said to reflect 'large' differences between the disease group and the general population [36] . The z-score scale also relates to percentiles of the adjusted score distribution of the general population. For example, z-scores of 1·96 or less equate to the lowest scoring 2·5% of the general population.
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functioning (P<0·0001) compared to the general population. Physical functioning, role limitation due to physical problems, social functioning, energy and general health perception are severely affected areas compared to the general population (P<0·0001). Fig. 2 shows the influence of gender on perceived quality of life (QoL) in people with heart failure, men having poorer QoL in emotion, energy and pain dimensions. Figure 3 shows the quality of life perceptions, subdivided by NYHA functional class at the time of patient assessment, i.e. on treatment in some cases. Deterioration in quality of life increases with the severity of their heart failure in all areas of health except for pain. NYHA classes II and III have similar detrimental effect on pain (II vs III, P=0·47) with NYHA IV having the greatest effect (II vs IV, P=0·0005; III vs IV, P=0·016). Figure 4 shows that the aetiology of heart failure had no influence on perceptions of quality of life.
Patients with asymptomatic left ventricular dysfunction (echocardiographic left ventricular ejection fraction of less than 40%) and patients rendered asymptomatic 
Heart failure LVSD and quality of life 1873
by treatment had similar scores to the random population (see Table 2 ). Figure 5 shows health perceptions of patients with heart failure compared with those with a history of other common cardiac conditions (angina, previous MI, atrial fibrillation or hypertension). Patients with heart failure have poorer perceptions of all areas of their quality of life (P<0·0001) except for pain in comparison to all other groups. Angina causes a greater effect on pain compared to heart failure (P=0·026). Those with hypertension have only slight impairment of the quality of life measures.
Overall, heart failure causes more severe impairment of physical functioning, role limitation due to physical problems and lack of energy, than chronic lung disease or arthritis (P<0·0001). Patients with arthritis score worse for pain (P<0·0001), and those with depression worse on role limitations due to emotional problems (P<0·0001) and mental health (P<0·0001) measures than those with heart failure (Fig. 6) .
Discussion
Overall quality of life is more than just the presence or absence of disease, or even symptoms. Physical, mental and social functioning are important components to perceptions of health or illness, but these factors are not routinely assessed by most practising physicians. We show unequivocally, for the first time, that patients with heart failure, diagnosed using strict criteria and regardless of aetiology, suffer statistically significant impairment of all eight measured areas of health, not simply physical functioning.
Since the same normative data were used for all the comparisons, including in the general population some patients with heart failure, the degree of impairment would be likely to be even greater if compared with a disease-free population. These data do show a gender difference in quality of life impairment, but unlike data from a much smaller study [17] , those worse affected were men, with significant differences in role limitations due to emotional problems, lack of energy, and pain.
A major strength of this study is the availability of contemporaneous and reliable reference population data. These data were obtained, using the same methodology, from a randomly selected representative population, stratified to balance socioeconomic status, and residing in the same areas as cases. In previous studies of quality of life using the SF36, historic population reference values from postal surveys have been used [31] or samples are small and non-representative. There is no upper age cut-off in the ECHOES study, and the demographics of the patients attending the study closely resemble those of the national population.
Patients with heart failure have worse health perceptions than patients with angina in all the domains, apart from pain. They also fare worse than those giving a history of chronic bronchitis and emphysema. However, it is possible that those who attended for screening may represent the mild end of the spectrum of respiratory disease: heart failure was assessed on stricter criteria than other conditions. Patients with hypertension are shown to have small but consistent impairment of all the measured aspects of health. Explanations for this finding include the condition itself causing minor impairment of quality of life; the adverse effects of antihypertensive medication; or that some patients suffered complications of their hypertension, such as strokes or symptomatic coronary heart disease.
The rapidly assessed NYHA functional classification of heart failure, based on the scale of symptoms, is shown to also reflect patients' own overall health perceptions. Those with more severe heart failure have more severe limitation of social functioning, and more severe impairment of the measures of mental health, than those with mild heart failure. Indeed there is a remarkably consistent and significant incremental increase in the impact of heart failure on quality of life with worsening NYHA class. Physicians can reasonably assume that improvements in a patient's NYHA functional classification are also likely to be associated with improved quality of life, and visa versa.
Those patients who previously had symptomatic heart failure but whose dyspnoea had improved to NYHA Class I on treatment have similar health perceptions to the general population, as did those with impaired LV function but no dyspnoeic symptoms on clinical history taking. Since treatment with ACE inhibitors significantly reduces progression to clinical heart failure, and can improve NYHA class, such treatment might be expected to have a major impact on overall quality of life as well as survival, as was observed here.
In contrast to results of the SOLVD investigators [32] and Jenkinson et al. [33] , our data show that those with LVSD, rendered asymptomatic on appropriate treatment, have health perceptions similar to randomly selected subjects, suggesting that treatment does have an impact on overall quality of life. Indeed, this study reinforces the view that quality of life should be a much more important target for management, such as enhanced use of ACE inhibitors and beta-blockers, drugs shown to improve quality of life as well as symptoms. Some treatments for heart failure, such as positively inotropic phosphodiesterase inhibitors, may improve some aspects of quality of life, but at the expense of increased mortality [35] ; yet despite this adverse profile, the benefits of such treatment were not dismissed by patients.
Overall, these data unequivocally show that in addition to being a malignant condition in terms of prognosis, heart failure causes malignant impairment of quality of life in sufferers. The degree of impairment is significantly greater than that seen in other cardiac conditions and major non-cardiac diseases. Given the poor prognosis of heart failure, equivalent to developing colorectal cancer, quality of life should be factored more actively into treatment decisions with patients, analogous to palliative treatments used in cancers. Most of the evidence-based treatments used in heart failure that significantly improve prognosis and symptoms also improve quality of life. However, these treatments remain under-utilised and under-dosed in many patients with heart failure, especially the elderly where longevity may not be the dominant indication. Improving overall health assessment should become a primary outcome for healthcare interventions in all patients with heart failure and is at least as important a goal for management as prognosis or healthcare utilisation.
